Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022
For the full year, sales was INR 2,793.88 million compared to INR 2,313.33 million a year ago. Revenue was INR 2,843.6 million compared to INR 2,335.61 million a year ago. Net income was INR 476.58 million compared to INR 381.37 million a year ago. Basic earnings per share from continuing operations was INR 47.66 compared to INR 38.14 a year ago. Diluted earnings per share from continuing operations was INR 47.66 compared to INR 38.14 a year ago.